annb0t
Top 20
LONDON, UK / ACCESSWIRE / September 7, 2022 / Kazia Therapeutics' FY22 results recapped a busy year focused on strengthening its oncology-focused pipeline. While the year was marked by encouraging data readouts from several preclinical/clinical programs (particularly in rare childhood brain cancers and brain metastases), this was partially offset by recent news that lead asset paxalisib (PI3K/mTOR inhibitor) has not graduated to Stage 2 of the Phase III GBM AGILE study in glioblastoma multiforme...
>>> Read more: Kazia Therapeutics (KZIA): Doubling Down on Clinical Development
>>> Read more: Kazia Therapeutics (KZIA): Doubling Down on Clinical Development
